Aquestive Therapeutics, Inc. (AQST): Results of Operations and Financial Condition
Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026-ex991earningsrelease.htm EX-99.1 Document Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephr
How this was made
The 30-second read
Why it matters
The company states it completed the human factors validation study and PK study to address CRL deficiencies, with preliminary PK endpoint success and no administration errors or serious adverse events in the self-administration arm. It reaffirms resubmission in Q3 2026 and outlines ex-U.S. filing plans.
Market read
This 8-K is a regulatory progress update that can shift traders’ probability-weighting for Anaphylm’s FDA path, especially with a reaffirmed Q3 2026 resubmission timeline.
What to watch
The 8-K reiterates guidance but does not provide new FDA decision dates; traders may over-weight the study results versus the remaining regulatory review uncertainty.
Background
Aquestive’s Anaphylm (dibutepinephrine) received an FDA Complete Response Letter on Jan 30, 2026, prompting required packaging and related work before resubmission.
Ticker impact
AQST reports Q2 2026 Anaphylm progress, including completion of human factors and PK studies and reaffirmed NDA resubmission in Q3 2026.
Bias upward into the Q3 2026 resubmission window, with volatility around any FDA feedback or resubmission execution details.
The filing is a primary 8-K with concrete regulatory-study outcomes and a reiterated resubmission schedule, which can re-rate probability of approval and launch readiness.
Market effects
Reinforces investor appetite for non-invasive epinephrine delivery platforms and FDA re-engagement after a CRL, potentially lifting sentiment for similar specialty pharma programs.
Limited direct regional read-through; mentions Canada and EU filing timelines for Anaphylm.
Moderate, as the update includes planned ex-U.S. regulatory submissions (Canada by end-2026, EU in Q1 2027) that can broaden the addressable market narrative.
Counterpoint
Even with improved human factors and PK endpoints, FDA expedited review is requested but not guaranteed, so approval timing risk remains high.
Key entities
- companyAquestive Therapeutics, Inc.
NASDAQ-listed pharma company advancing Anaphylm and the AdrenaVerse epinephrine prodrug platform.
- product_candidateAnaphylm (dibutepinephrine) sublingual film
Oral epinephrine product candidate for type I allergic reactions, including anaphylaxis, targeted for FDA resubmission in Q3 2026.
- product_candidateAQST-108 (epinephrine) topical gel
Topical epinephrine prodrug gel in early development for dermatologic indications, including atopic dermatitis.
- regulatorFDA
Regulatory authority that issued the Jan 30, 2026 Complete Response Letter and will review the forthcoming NDA resubmission.
